Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
HRP Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-08-13
The HRP Rabbit Anti-Goat IgG (H+L) Antibody is a horseradish peroxidase conjugated secondary antibody for immunodetection of goat primary antibodies. Product-listed formulation, storage conditions, and application-specific dilution ranges support reproducible ELISA, western blot, dot blot, and tissue-staining workflows.
Y-27632: From ROCK Biology to Translation
2026-08-12
Y-27632 offers a reversible, selective way to interrogate ROCK-dependent cytoskeletal behavior while opening a carefully bounded research bridge to the LPS/TLR4/YAP1 stemness axis described in hepatocytes. This thought-leadership perspective translates that mechanistic opportunity into experimental design, product-selection criteria, and translational strategy.
Z-IETD-FMK: Reliable Caspase-8 Assays
2026-08-12
Learn how Z-IETD-FMK (SKU B3232) can help researchers distinguish caspase-8-dependent apoptosis from general metabolic decline, optimize T-cell assays, and interpret complex cell-death phenotypes. This scenario-based guide links formulation, controls, pathway biology, and vendor-selection considerations to practical laboratory decisions.
Bafilomycin C1 in High-Content Cell Assays
2026-08-11
Bafilomycin C1 turns lysosomal acidification into a controllable experimental variable for autophagy, toxicity, and high-content phenotyping workflows. This guide pairs V-ATPase inhibition with iPSC-cardiomyocyte imaging, practical dose-finding, and troubleshooting strategies that help distinguish organelle stress from direct electrophysiological injury.
Chlorambucil Workflows for Cancer Drug Response
2026-08-11
Build more informative Chlorambucil experiments by separating growth inhibition from actual cell killing. This workflow covers solvent handling, time-resolved viability and apoptosis measurements, model-specific interpretation, and troubleshooting for leukemia, glioma, and comparative cell studies.
ECL Chemiluminescent Substrate Detection Kit Guide
2026-08-09
The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) supports HRP-based immunoblotting when low-abundance protein bands are difficult to visualize. It is intended for research use with nitrocellulose or PVDF membranes and should not be used for diagnostic, clinical, or medical applications.
MG-262: Mapping Proteostasis in Inflamed Lung Cells
2026-08-08
MG-262, or Z-Leu-Leu-Leu-B(OH)2, enables reversible interrogation of proteasome function at the intersection of inflammation, ubiquitin signaling, and epithelial cell fate. This article translates cytokine and glucocorticoid findings into a mechanistically controlled proteasome inhibition assay strategy.
(5Z)-7-Oxozeaenol in Stress-Signaling Assays
2026-08-07
Explore how the TAK1 inhibitor (5Z)-7-Oxozeaenol can clarify the AMPK–SQSTM1 stress-response circuit. This article translates recent mechanistic findings into assay-design decisions while distinguishing metabolic-stress evidence from inflammation applications.
Palomid 529 (P529): A Next-Generation PI3K/Akt/mTOR Inhibito
2026-08-07
Explore how Palomid 529 (P529), a potent dual mTORC1/2 inhibitor, is reshaping cancer research through advanced pathway targeting and radiotherapy enhancement. Uniquely, we analyze the translational impact and protocol strategies beyond what existing resources provide.
Vincristine Sulfate: Optimized Protocols for Cancer Research
2026-08-06
Vincristine sulfate, a microtubule disrupter from APExBIO, empowers cancer research with proven anti-proliferative effects and versatile protocol adaptability. This guide details stepwise workflows, troubleshooting strategies, and novel assay insights for maximizing reproducibility and translational value in oncology labs.
Technical Guide to Cathepsin B Inhibitor CA-074 (SKU A1926)
2026-08-06
Cathepsin B inhibitor CA-074 (SKU A1926) is a potent, selective tool for dissecting the role of cathepsin B in processes like cancer metastasis, neurodegeneration, and immune modulation. It is recommended where rigorous, mechanistically grounded inhibition of cathepsin B is required, but should not be used as a pan-cathepsin or broad-spectrum cysteine protease inhibitor due to its high selectivity.
Golgi-Tracker Green: Advancing Live-Cell Golgi Apparatus Lab
2026-08-05
Golgi-Tracker Green leverages BODIPY FL-labeled C5-ceramide to deliver precise, photostable labeling of the Golgi in live cells—outperforming legacy probes. Discover how its specificity empowers robust workflows in lipid transport and sphingolipid metabolism analysis, with actionable troubleshooting and protocol guidance for dynamic cellular imaging.
Sunitinib: Multi-Targeted RTK Inhibitor in Renal Cell Carcin
2026-08-05
Sunitinib, a potent multi-targeted receptor tyrosine kinase inhibitor, enables advanced interrogation of tumor angiogenesis, proliferation, and apoptosis in cancer models. Recent breakthroughs in combination strategies, like chrysin-induced ferroptosis, offer new solutions for overcoming resistance and optimizing experimental outcomes in renal cell carcinoma research.
Haloprogin: Broad-Spectrum Antifungal Agent for Dermatophyte
2026-08-04
Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) is a potent topical antimicrobial with demonstrated efficacy against dermatophytes, yeasts, and Gram-positive bacteria. Its low MIC values and robust in vivo performance establish it as a benchmark for dermatophytosis and Candida research. This article synthesizes key evidence, protocol parameters, and practical integration for laboratory and translational workflows.
IDO1 Inhibition Unmasks Tumor-Protective STAT3 Activation
2026-08-04
This study reveals that pharmacological inhibition of IDO1, while intended to enhance anti-tumor immunity, paradoxically activates the tumor-intrinsic JAK2/STAT3 pathway via IL-6, resulting in tumor-protective effects. The findings underscore the need for combined therapeutic strategies that target both IDO1 and JAK2/STAT3 signaling to overcome resistance in cancer immunotherapy.
8651 records 12/577 page Previous Next First page 上5页 1112131415 下5页 Last page